European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“Management of metastatic pancreatic cancer: ESMO Clinical Practice Guideline Express Update Metastatic pancreatic cancer management continues to make significant progress. This CPG Express Update includes updates to first- and second-line treatment recommendations and corresponding treatment algorithm, following the approval of first-line nanoliposomal irinotecan.”